p53: Prospects for cancer gene therapy

Cytokines, Cellular and Molecular Therapy

Volumn 4, Issue 3, 1998, Pages 177-185

  Soddu, Silvia ^a   Sacchi, Ada ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Apoptosis; Drug resistance; Gene therapy; p53 tumor suppressor; Tumor targeting

Indexed keywords

APOPTOSIS; ARTICLE; CANCER; CANCER THERAPY; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CELL TRANSFORMATION; CELL TYPE; GENE OVEREXPRESSION; GENE THERAPY; GENETIC TRANSDUCTION; GROWTH DISORDER; PHENOTYPE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ANIMALS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE TARGETING; GENE THERAPY; HUMANS; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031719125     PISSN: 13684736     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Gottlieb TM, Oren M, p53 in growth control and neoplasia. Biochim Biophys Acta (1996) 1287: 77-102.
2. Donehower LA, Harvey M, Slagle BL et al, Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature (1992) 356: 215-21.
3. Malkin D, Li FP, Strong LC et al, Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms. Science 250: 1233-8.
4. Ozturk M, Ponchel F, Pulsleux A, p53 as a potential target in cancer therapy. Bone Marrow Transplant (1992) 9(Suppl 1): 164-70.
5. Oren M, Prives C, p53: upstream, down stream and off stream. Biochim Biophys Acta (1996) 1288: 13-19.
6. Roth JA, Cristiano RJ, Gene therapy for cancer: What have we done and where are we going? J Natl Cancer Inst (1977) 89: 21-39.
7. Roth JA, Nguyen D, Lawrence DD et al, Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nature Med (1996) 2: 985-91.
8. Hupp TR, Sparks A, Lane DP, Small peptides activate the latent sequence-specific DNA binding function of p53. Cell (1995) 83: 237-45
9. Bischoff JR, Kirn DH, Williams A et al, An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science (1996) 274: 373-6.
10. Farmer G, Bargonetti J, Zhu H et al, Wild-type p53 activates transcription in vitro. Nature (1992) 358: 83-6.
11. Kern SE, Kinzler KW, Bruskin A et al, Identification of p53 as a sequence-specific DNA-binding protein. Science (1991) 252: 1708-11.
12. Waldman T, Kinzler KW, Volgestein B, p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res (1995) 55: 5187-90.
13. Hermeking H, Lengauer C, Polyak K et al, 14.3.3 is a p53-regulated inhibitor of G2/M progression. Mol Cell (1997) 1: 3-11.
14. Almog N, Rotter V, Involvement of p53 in cell differentiation and development. Biochim Biophys Acta (1997) 1333: 1-27.
15. Soddu S, Blandino G, Scardigli R et al, Interference with p53 protein inhibits hematopoietic and muscle differentiation. J Cell Biol (1996) 134: 11-12.
16. Caelles C, Helmberg A, Karim M, p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature (1994) 370: 220-3.
17. Haupt Y, Rowan S, Shaulian E et al, Induction of apoptosis in HeLa cells by trans-activation-deficient p53. Genes Dev (1995) 9: 2170-83.
18. Wagner AJ, Kokontis JM, Hay N, Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21 Genes Dev (1994) 8: 2817-30.
19. Attardi LD, Lowe SW, Brugarolas J, Jacks T, Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis. EMBO J (1996) 15: 3683-701.
20. Gottlieb E, Lindner S, Oren M, Relationship of sequence-specific transactivation and p53-regulated apoptosis in interleukin 3-dependent hematopoietic cells. Cell Growth Differentiation (1996) 7: 301-10.
21. Eliyahu D, Michalovitz D, Eliyahu S et al, Wild-type p53 can inhibit oncogene-mediated focus formation. Proc Natl Acad Sci USA (1989) 86: 8763-7.
22. Finlay CA, Hinds PW, Levine AJ, The p53 proto-oncogene can act as a suppressor of transformation. Cell (1989) 57: 1083-93.
23. Jacks T, Weinberg RA, Cell-cycle control and its watchman. Nature (1996) 381: 643-4.
24. Polyak K, Waldman T, He TC et al, Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev (1996) 10: 1945-52.
25. Haupt Y, Rowen S, Oren M, p53-mediated apoptosis in HeLa cells can be overcome by excess pRB. Oncogene 91995) 10: 1563-1.
26. Sandig V, Brand K, Herwig S et al, Adenovirally transferred p16INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death. Nature Med (1997) 3: 313-19.
27. Xiao ZX, Chen J, Levine AJ et al, Interaction between the retinoblastoma protein and the oncoprotein mdm2. Nature (1995) 375: 694-7.
28. Canman CE, Gilmer TM, Coutts SB, Kastan MB, Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes Dev (1995) 9: 600-11.
29. Soddu S, Blandino G, Scardigli R et al, Wild type p53 induces diverse effects in 32D cells expressing different oncogenes. Mol Cell Biol (1996) 16: 487-95.
30. Lotem J, Peled-Kamar M, Groner Y, Sachs L, Cellular oxidative stress and the control of apoptosis by wild-type p53 cytotoxic compounds and cytokines. Proc Natl Acad Sci USA (1996) 93: 9166-71.
31. Yonish-Rouach E, Resnitzky D, Lotem J et al, Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature (1991) 352: 345-7
32. Blandino G, Scardigli R, Rizzo MG et al, Wild-type p53 modulates apoptosis of normal, IL-3 deprived, hematopoietic cells. Oncogene (1995) 10: 731-7.
33. Lowe SW, Cancer therapy and p53. Curr Opin Oncol (1995) 7: 547-53.
34. Rizzo MG, Zapparoni A, Cristofanelli B et al, Wt-p53-action in human leukemia cell lines corresponding to different stages of differentiation. Br J Cancer (1998) 77: 1429-38.
35. Fisher D, Apoptosis in cancer therapy: crossing the threshold. Cell (1994) 78: 539-42.
36. Lowe SW, Ruley HE, Jacks T, Housman DE, p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell (1993) 74: 957-67.
37. Lowe SW, Bodis S, McClatchey A et al, p53 status and the efficacy of cancer therapy in vivo. Science (1994) 266: 807-10.
38. Fan S, Smith ML, Rivet DJ et al, Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res (1995) 55: 1649-54.
39. Hawkins DS, Demers WGW, Galloway DS, Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res (1996) 56: 892-8.
40. Wu GS, El-Deiry WS, Apoptotic death of tumor cells correlates with chemosensitivity, independently of p53 or bcl-2. Clin Cancer Res (1996) 2: 623-33.
41. Del Bufalo D, Biroccio A, Soddu S et al, Lonidamine induces apoptosis in drug-resistant cell independently of the p53 gene. J Clin Invest (1996) 98: 1165-73.
42. Kasahara N, Dozy AM, Kan YW, Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. Science (1994) 266: 1373-6.
43. Etienne-Julan M, Roux P, Bourquard P et al, Cell targeting by murine recombinant retroviruses. Bone Marrow Transplant (1992) 9(Suppl 1): 139-42.
44. Ferrari G, Salvatori G, Rossi C et al, A retroviral vector containing a muscle-specific enhancer drives gene expression only in differentiated muscle fibers Hum Gene Ther (1995) 6: 733-42.
45. Baker SJ, Markowitz S, Fearon ER et al, Suppression of human colorectal carcinoma cell growth by wild-type p53. Science (1990) 249: 912-15.
46. Clayman GL, el-Naggar AK, Roth JA et al, In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res (1995) 55: 1-6.
47. Lesoon-Wood LA, Kim WH, Kleinman HK et al, Systemic gene therapy with p53 reduces growth and metastases of a malignant human breast cancer in nude mice. Hum Gene Ther (1995) 6: 395-405.
48. Wills KN, Maneval DC, Menzel P et al, Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Hum Gene Ther (1994) 5: 1079-88.
49. Zhang WW, Alemany R, Wang J et al, Safety evaluation of Ad5CMS-p53 in vitro and in vivo. Hum Gene Ther (1995) 6: 155-64.
50. Hwu P, Rosenberg SA, Gene therapy of cancer. In: Cancer: Principles and Practice of Oncology, 5th edn (ed VT De Vita Jr, S Hellman, SA Rosenberg) 3005-21. Lippincott-Raven, Philadelphia, 1997.
51. Scardigli R, Bossi G, Blandino G et al, Expression of exogenous wt-p53 does not affect normal hematopoiesis: implications for bone marrow purging. Gene Ther (1997) 4: 1371-8.
52. Graeber TG, Osmanian C, Jacks T et al, Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature (1996) 379: 88-91.
53. Kastan, MB, Onyekwere O, Sidransky D et al, Participation of p53 protein in the cellular response to DNA damage. Cancer Res (1991) 51: 6304-11.
54. 1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes Dev (1996) 10: 934-47.
55. Hansen R, Oren M, p53: from inductive signal to cellular effect. Curr Opin Genet Dev (1997) 7: 46-51.
56. Hupp TR, Lane DP, Allosteric activation of latent p53 tetramers. Curr Biol (1994) 4: 865-75.
57. Hupp TR, Meek DW, Midgley CA, Lane DP, Regulation of the specific DNA binding function of p53. Cell (1992) 71: 875-86.
58. Bargonetti J, Manfredi JJ, Chen X et al, A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. Genes Dev (1993) 7: 2565-74.
59. Abarzua P, LoSardo JE, Gubler ML et al, Restoration of the transcription activation function to mutant p53 in human cancer cells. Oncogene (1996) 13: 2477-82.
60. Halazonetis TD, Kandil AN, Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants. EMBO J (1993) 12: 5057-64.
61. Hupp TR, Meek DW, Midgley CA, Lane DP, Activation of the cryptic DNA binding function of mutant forms of p53. Nucleic Acid Res (1993) 21: 3167-74.
62. Niewolik D, Vojtesek B, Kovarik J, p53 derived from human tumor cell lines and containing distinct point mutations can be activated to bind its consensus target sequence. Oncogene (1995) 10: 881-90.
63. Abarzua P, LoSardo JE, Gubler ML, Neri A, Microinjection of monoclonal atibody Pab421 into human SW480 colorectal carcinoma cells restores the transcription activation function to mutant p53. Cancer Res (1995) 55: 3490-4.
64. Selivanova G, Iotsova V, Okan I et al, Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nature Med (1997) 3: 632-8.
65. Heise C, Sampson-Johannes A, Williams A et al, ONYX-015, an ElB gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nature Med (1997) 3: 639-45.
66. Bramson JL, Itt M, Gauldie J, Graham FL, Pre-existing immunity to adenovirus does not prevent tumor regression following intratumural administration of a vector expressing IL-12 but inhibits virus dissemination. Gene Ther (1997) 4: 1069-76.